Impact of guidelines and enhanced antibiotic stewardship on reducing broad-spectrum antibiotic usage and its effect on incidence of Clostridium difficile infection

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 9, 2011, Pages 2168-2174

  Talpaert, Moïra Joëlle ^a   Rao, Guduru Gopal ^b   Cooper, Ben Symons ^c,d   Wade, Paul ^e  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b NORTHWICK PARK HOSPITAL   (United Kingdom)

^c MAHIDOL UNIVERSITY   (Thailand)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antibiotics; CDI; Cephalosporins; Fluoroquinolones; Interrupted time series

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEPHALOSPORIN; CLARITHROMYCIN; CLINDAMYCIN; DOXYCYCLINE; GENTAMICIN; MACROLIDE; NITROFURANTOIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TRIMETHOPRIM; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC STEWARDSHIP PROGRAM; ANTIBIOTIC THERAPY; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; DRUG SAFETY; DRUG USE; HEALTH PROGRAM; HUMAN; INCIDENCE; INFECTION RISK; NONHUMAN; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; DATA COLLECTION; DRUG UTILIZATION; GUIDELINES AS TOPIC; HUMANS; INFECTION CONTROL; LONDON; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RIBOTYPING; TREATMENT OUTCOME;

EID: 80051679970     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr253     Document Type: Article

References (23)

1. HPA. Results of first year of mandatory Clostridium difficile reporting: January to December 2004. CDR Weekly 2005; 15: 24-6.
2. Mooney H. Annual incidence of MRSA falls in England, but C. difficile continues to rise. BMJ 2007; 335: 958.
3. Golledge CL, McKenzie T, Riley TV. Extended spectrum cephalosporins and Clostridium difficile. J Antimicrob Chemother 1989; 23: 929-31.
4. Impallomeni M, Galletly NP, Wort SJ et al. Increased risk of diarrhoea caused by Clostridium difficile in elderly patients receiving cefotaxime. BMJ 1995; 311: 1345-6.
5. Settle CD, Wilcox MH, Fawley WN et al. Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam. Aliment Pharmacol Ther 1998; 12: 1217-23.
6. McCusker ME, Harris AD, Perencevich E et al. Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg Infect Dis 2003; 9: 730-3.
7. Muto CA, Pokrywka M, Shutt K et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005; 26: 273-80.
8. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect 1998; 40: 1-15.
9. Silva J, Fekety R,Werk C et al. Inciting and etiologic agents of colitis. Rev Infect Dis 1984; 6 Suppl 1: S214-21.
10. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2011. http://www.whocc.no/atc_ddd_index/ (10 April 2011, date last accessed).
11. Fowler S, Webber A, Cooper BS et al. Successful use of feedback to improve antibiotic prescribing and reduce Clostridium difficile infection: a controlled interrupted time series. J Antimicrob Chemother 2007; 59: 990-5.
12. Wagner AK, Soumerai SB, Zhang F et al. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002; 27: 299-309.
13. Aldeyab MA, Monnet DL, Lopez-Lozano JM et al. Modelling the impact of antibiotic use and infection control practices on the incidence of hospital-acquired methicillin-resistant Staphylococcus aureus: a time-series analysis. J Antimicrob Chemother 2008; 62: 593-600.
14. Stone SP, Cooper BS, Kibbler CC et al. The ORION statement: guidelines for transparent reporting of outbreak reports and intervention studies of nosocomial infection. J Antimicrob Chemother 2007; 59: 833-40.
15. Aldeyab MA, Harbarth S, Vernaz N et al. Quasiexperimental study of the effects of antibiotic use, gastric acid-suppressive agents, and infection control practices on the incidence of Clostridium difficile-associated diarrhea in hospitalized patients. Antimicrob Agents Chemother 2009; 53: 2082-8.
16. Bartlett JG. Antibiotic-associated colitis. Dis Mon 1984; 30: 1-54.
17. British Thoracic Society. BTS guidelines for the management of community acquired pneumonia in adults. Thorax 2001; 56 Suppl IV: iv1-64.
18. British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. Br J Hosp Med 1993; 49: 346-50.
19. Gopal RG, Mahankali Rao CS, Starke I. Clostridium difficile-associated diarrhoea in patients with community-acquired lower respiratory infection being treated with levofloxacin compared with β-lactam-based therapy. J Antimicrob Chemother 2003; 51: 697-701.
20. Hillman RJ, Rao GG, Harris JR et al. Ciprofloxacin as a cause of Clostridium difficile-associated diarrhoea in an HIV antibody-positive patient. J Infect 1990; 21: 205-7.
21. McFarland LV, Clarridge JE, Beneda HW et al. Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a Veterans Administration health care system. Clin Infect Dis 2007; 45: 1141-51.
22. Pelle B, Weal GML. Using defined daily doses to study the use of antibacterials in UK hospitals. Hosp Pharm 2006; 13: 133-6.
23. Histon L, Patel M, Rao G. Do changes in antibiotic guidelines result in reduction in healthcare acquired infections? In: Communications to the Autumn Meeting of the British Geriatric Society, Harrogate, Yorkshire, UK, 2007. Abstract 11, p.13. http://www.bgs.org.uk/PDF%20Downloads/Abstracts%20Autumn2007.pdf (8 May 2011, date last accessed).